drugset / Trial / NCT04603001
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
Timeline
- Start
- 2020-11-19
- Primary completion
- 2023-07-03
- Completion
- 2026-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | CRELOSIDENIB | Small molecule | — | Oral |
| Subject | Venetoclax | Small molecule | — | Oral |